Stock listing

Xetra:26CA ImmunityBio, Inc. Aktie

German listing (Xetra) of ImmunityBio, Inc. · home listing NASDAQ:IBRX

Follow ImmunityBio, Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:IBRX

$6.02 USD -0.68 (-10.1%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:IBRX

Past year +198.0% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$6.00 – $6.53 USDNov 20, 2026
Volume
10.57M sharesNov 20, 2026
Market cap
$6.40B USDAt the close on Nov 20, 2026 · price × 1.06B shares outstanding
52-week range
$1.95 – $12.43 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$108.3M USDMedian day 11.06M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
ImmunityBio, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:IBRX · Home$6.02 USD-0.68 (-10.1%)10,565,228$6.41$6.53$6.00$6.70Close on Nov 20, 2026
Frankfurt:26CA€5.51 EUR-0.45 (-7.6%)—€5.86€5.86€5.51€5.96Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:IBRX · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$6.02-0.68-10.1%$6.41$6.53$6.0010,565,228
$6.70+0.44+7.0%$6.255$6.78$6.1215,772,893
$6.26+0.28+4.7%$6.13$6.38$6.0811,471,950
$5.98-0.04-0.7%$5.87$6.14$5.7612,799,375
$6.02-0.05-0.8%$6.09$6.17$5.8313,302,272
$6.07-0.60-9.0%$6.45$6.50$6.0020,957,501
$6.67-0.075-1.1%$6.847$6.847$6.5111,934,176
$6.745-0.365-5.1%$6.97$7.27$6.6120,007,921
$7.11-1.525-17.7%$7.23$7.345$6.3644,767,080
$8.635+0.625+7.8%$8.17$8.69$7.8819,215,309
$8.01-0.92-10.3%$8.78$8.79$8.0012,504,489
$8.93+0.64+7.7%$8.42$8.95$8.2059,706,618
$8.29+0.34+4.3%$8.00$8.425$7.976,175,086
$7.95-0.34-4.1%$8.32$8.39$7.939,031,814
$8.29-0.45-5.1%$8.48$8.72$8.1228,911,096
$8.74-0.07-0.8%$8.75$8.935$8.567,113,047
$8.81+0.18+2.1%$8.66$8.83$8.487,136,872
$8.63+0.82+10.5%$7.84$8.685$7.76510,486,483
$7.81-0.41-5.0%$8.255$8.28$7.7510,960,202
$8.22-0.09-1.1%$8.22$8.355$8.055,922,752
$8.31-0.33-3.8%$8.51$8.84$8.0212,731,345
$8.64-0.13-1.5%$8.88$8.99$8.3211,462,803
$8.77+0.35+4.2%$8.31$8.90$8.1113,971,629
$8.42-0.76-8.3%$9.19$9.697$8.3119,509,986
$9.18-0.82-8.2%$10.02$10.02$9.0221,485,000
$10.00+0.09+0.9%$10.20$10.50$9.81520,010,100
$9.91+0.11+1.1%$9.69$10.46$9.3530,228,600
$9.80-0.32-3.2%$10.00$10.06$9.5611,604,000
$10.12-0.39-3.7%$10.59$10.62$10.0511,057,100
$10.51+0.60+6.1%$9.95$10.80$9.8718,657,500
$9.91+0.16+1.6%$9.63$10.05$9.4310,492,100
$9.75+0.06+0.6%$9.50$9.93$9.3311,780,000
$9.69-0.69-6.6%$10.33$10.36$9.6116,887,000
$10.38+0.095+0.9%$10.76$10.81$10.1316,866,900
$10.29+1.005+10.8%$9.39$10.55$9.3931,251,600
$9.28-0.16-1.7%$9.28$9.40$9.0712,313,700
$9.44+0.61+6.9%$8.92$10.09$8.9027,286,800
$8.83+0.31+3.6%$8.52$8.88$8.528,366,600
$8.52+0.08+0.9%$8.39$8.979$8.2610,413,600
$8.44-0.20-2.3%$8.76$8.84$8.415,819,400
$8.64+0.01+0.1%$8.50$8.675$8.318,980,000
$8.63-0.66-7.1%$9.26$9.29$8.6013,954,500
$9.29+0.84+9.9%$8.45$9.48$8.3721,133,200
$8.45-0.03-0.4%$8.72$8.87$8.2612,238,200
$8.48+0.02+0.2%$8.46$8.53$8.2018,428,900
$8.46+0.55+7.0%$8.14$8.80$8.1219,159,300
$7.91-0.23-2.8%$8.135$8.30$7.769,205,000
$8.14-0.23-2.7%$8.32$8.34$7.858,949,300
$8.37+0.46+5.8%$7.89$8.40$7.879,158,300
$7.91+0.19+2.5%$7.80$8.345$7.8012,468,800
$7.72-0.34-4.2%$7.87$7.89$7.648,797,200
$8.06-0.23-2.8%$8.22$8.36$7.8759,485,900
$8.29+0.21+2.6%$8.00$8.37$7.937,735,300
$8.08-0.11-1.3%$8.08$8.24$8.014,324,700
$8.19+0.24+3.0%$8.00$8.21$7.885,271,800
$7.95+0.08+1.0%$7.945$8.28$7.7557,228,300
$7.87-0.08-1.0%$7.82$7.99$7.736,460,300
$7.95-0.10-1.2%$7.88$8.02$7.846,873,400
$8.05-0.35-4.2%$8.31$8.32$7.9457,980,000
$8.40+0.15+1.8%$8.24$8.76$8.1812,311,500
$8.25+0.06+0.7%$8.17$8.40$8.079,446,500
$8.19+0.61+8.0%$7.69$8.23$7.6811,547,390
$7.58-0.21-2.7%$7.68$7.72$7.465,671,527
$7.79-0.05-0.6%$7.85$7.95$7.607,619,700
$7.84-0.29-3.6%$7.90$8.00$7.748,099,200
Ticker
Xetra:26CA
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Xetra
Currency
EUR

What changed lately

Latest news

All ImmunityBio, Inc. news

ImmunityBio, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
54 in the last 12 months · 210 in all · newest Nov 19, 2026 · oldest 2019
Decks
10 decks · latest August 2026

Where ImmunityBio, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:IBRX · Home listingNASDAQUnited StatesUSD
gettex:26CAgettexGermanyEUR
LS Exchange:A2QQ2ELS ExchangeGermanyEUR
Tradegate:26CATradegateGermanyEUR
BOATS:IBRXBOATSUnited StatesUSD
Frankfurt:26CAFrankfurtGermanyEUR
Lang & Schwarz:A2QQ2ELang & SchwarzGermanyEUR
Dusseldorf:26CADusseldorfGermanyEUR
Stuttgart:26CAStuttgartGermanyEUR
Munich:26CAMunichGermanyEUR
Hamburg:26CAHamburgGermanyEUR
Hanover:26CAHanoverGermanyEUR
Xetra:26CA · This pageXetraGermanyEUR
BMV:IBRXBMVMexicoMXN

Valuation

EV/sales 33.4× against a median of 56.2×: 4th lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$6.10B USD
P/E
Loss
EV/sales
33.4×
EV/EBITDA
Negative EBITDA
Price/book
Negative equity
Gross margin
96.7%
Operating margin
−150.2%
Net margin
−607.8%
Debt to equity
Negative equity
Beta vs S&P 500
1.50

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
ImmunityBio, Inc. · NASDAQ:IBRXUS$6.40BUS$6.10Bn/a33.4×n/an/a−607.8%n/a1.50
CG Oncology, Inc. · NASDAQ:CGONUS$7.10BUS$6.12Bn/a992×n/a7.2×n/a0.0×0.83
Cytokinetics, Incorporated · NASDAQ:CYTKUS$7.07BUS$6.36Bn/a56.2×n/an/a−686.6%n/a0.93
Axsome Therapeutics, Inc. · NASDAQ:AXSMUS$6.80BUS$6.68Bn/a7.7×n/a64.5×−18.2%1.8×0.69
Akeso, Inc. · HKEX:9926US$6.66BUS$6.04Bn/a13.5×n/a5.2×−36.4%0.6×n/a
Immunovant, Inc. · NASDAQ:IMVTUS$6.57BUS$5.85Bn/a825×n/a10.0×n/a0.0×1.46
Oruka Therapeutics, Inc. · NASDAQ:ORKAUS$6.50BUS$5.58Bn/an/an/a5.4×n/a0.0×1.30
Kodiak Sciences Inc · NASDAQ:KODUS$6.35BUS$6.31Bn/an/an/a505×n/a3.7×1.58
Abivax SA · EURONEXT:ABVXUS$6.05BUS$5.60Bn/an/an/a15.1×n/a0.0×n/a
Scholar Rock Holding Corporation · NASDAQ:SRRKUS$5.87BUS$5.65Bn/a9,921×n/a34.8×n/a1.2×0.91
Arrowhead Pharmaceuticals, Inc. · NASDAQ:ARWRUS$5.85BUS$4.66Bn/a10.3×n/a116×−160.6%0.0×1.34
Median of the othersUS$6.54BUS$5.95B56.2×15.1×−98.5%0.0×1.12

Forecasts

3 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.

Price target
14.25 USD · Analysts' mean
EPS, year to Dec 2026
-0.93 · 1 analyst
Revenue, year to Dec 2026
201.8M · 3 analysts

Team and board

Officers

OfficerRole
Rich AdcockPresident & Chief Executive Officer
David SachsChief Financial Officer
Hemanth RamaprakashInvestor Relations
Bruce BrownSenior Vice President, Medical Affairs
Charles G. GarlisiSenior Vice President, Regulatory Affairs
Elizabeth GabitzschSenior Vice President, Product Development & Vaccine Programs
Emily ArisonSenior Vice President of Human Resources
Manju SaxenaSenior Vice President of Product Development, Cell Therapy Program
Barry SimonChief Corporate Affairs Officer
Enrique DilonéChief Technology Officer
Leonard S. SenderChief Medical Officer, Liquid Tumors & Cell Therapy
Matthew HilmanVice President US Commercial – Urologic Oncology
Patrick Soon-ShiongExecutive Chairman of the Board
Regan LauerChief Accounting Officer
Sandeep Bobby ReddyChief Medical Officer
Sarah SingletonChief Communications Officer & Head of Patient Advocacy

Board

DirectorRole
Jim Yong KimVice Chairman
Patrick Soon-ShiongExecutive Chairman of the Board
Bruce Wendel
Cheryl Cohen
Christobel Selecky
Linda Maxwell
Michael Blaszyk
Wesley Clark

Events

QuarterResultsShare move
Q3 2026Nov 9, 2026 · Before open−17.7%
Q2 2026Aug 4, 2026 · Before open−2.8%
Q1 2026May 7, 2026 · Before open−7.4%
Q4 2025Mar 3, 2026−13.8%
Q3 2025Nov 4, 2025 · After close+3.4%
Q2 2025Aug 5, 2025 · Before open0.0%
Q1 2025May 7, 2025 · After close+10.6%
Q4 2024Mar 3, 2025 · Before open−13.4%
Q3 2024Nov 12, 2024 · Before open−9.2%
Q2 2024Aug 12, 2024 · Before open−2.6%
All 20 quarters
QuarterResultsShare move
Q1 2024May 9, 2024 · After close+0.7%
Q4 2023Mar 19, 2024 · After close+10.3%
Q3 2023Nov 9, 2023 · Before open−17.1%
Q2 2023Aug 8, 2023 · After close−10.2%
Q1 2023May 11, 2023 · Before open−55.1%
Q4 2022Mar 1, 2023 · After close−10.6%
Q3 2022Nov 9, 2022 · Before open−10.7%
Q2 2022Aug 8, 2022 · After close−2.9%
Q1 2022May 10, 2022 · After close−22.3%
Q4 2021Mar 1, 2022 · After close−1.4%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (August 2026)Investor deck33 slidesAugust 2026
Milken Institute Presentation 2026Conference67 slidesFeb 24, 2026
Investor Presentation (November 2022)Investor deck30 slidesNov 15, 2022
Jefferies Healthcare Conference 2022Conference32 slidesJun 10, 2022
Investor Presentation (June 2021)Investor deck58 slidesJun 4, 2021
Investor Presentation (March 2021)Investor deck45 slidesMar 17, 2021
39th Annual JP Morgan Healthcare Conference 2021Conference35 slidesJan 13, 2021
NantKwest — Merger or Acquisition (December 2020)Merger or acquisition31 slidesDec 21, 2020
LifeSci Advisors Investor Call, May 27, 2020Conference18 slidesMay 27, 2020
NantKwest — Investor Day (December 2019)Investor day111 slidesDec 2, 2019

Open Decks

Financings

RaiseDate
Registered direct offering of common stock and warrants
Announced: about US$80M · Piper Sandler & Co.
Dealers: Piper Sandler & Co. (lead)
Use of proceeds: Further working capital and support for ongoing business operations
Jul 25, 2025
Registered direct offering of common stock and warrants
Announced: about US$75M · warrants for the purchase of additional shares of common stock; if fully exercised,…
Buyers: single institutional investor
Use of proceeds: Working capital and ongoing business operations
Apr 8, 2025
Public offering of common stock
Update: about US$100M · US$3 a share · Jefferies +4
Dealers: Jefferies (co-lead), Piper Sandler (co-lead), BTIG (co-lead), H.C. Wainwright & Co. (co-lead), D. Boral Capital
Use of proceeds: Commercialization of ANKTIVA for bladder cancer, trials in BCG-naive NMIBC and NSCLC, R&D, working capital and general corporate purposes
Dec 11, 2024

Open Financings · Read by 6ix AI from the company's releases

IPO

Went public as NantKwest, Inc. Priced at US$25.00 a share on Jul 27, 2015.

Price
US$25.00 a share
Shares offered
8,288,000 shares of common stock
Offering size
US$207.2 million
Underwriters' option
Up to 1,243,200 more shares
Underwriters
BofA Merrill Lynch, Citigroup, Jefferies, Piper Jaffray, MLV & Co. · In the order on the cover
Shares delivered
On or about Jul 31, 2015

Steps

StepWhen
Draft sent to the SEC in confidenceMay 14, 2015
Filed publiclyJun 19, 2015
Amended 6 timesNewest Jul 27, 2015
Shares registered with an exchangeJul 20, 2015
Declared effective by the SECJul 27, 2015
Final prospectus, with the priceJul 29, 2015

Open IPO · From the cover of the final prospectus (424B4) filed Jul 29, 2015

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue113.3M14.7M622.0K240.0K934.0K605.0K2.20M47.0K45.0K44.0K
Cost of revenue753.0K0009.15M9.01M-3.11M
Gross profit112.5M14.7M622.0K240.0K934.0K605.0K-8.97M3.16M45.0K44.0K
Research and development207.9M190.1M232.4M248.1M196.0M139.5M112.0M55.7M42.0M29.2M
Selling, general and administrative150.0M168.8M129.6M102.7M135.3M71.3M46.5M42.7M57.1M95.4M
Operating income-256.0M-344.2M-362.3M-351.3M-330.3M-220.9M-156.3M-98.4M-99.1M-124.5M
Depreciation and amortization15.5M17.6M18.5M18.3M14.2M12.7M14.0M9.55M5.57M3.61M
EBITDA-240.5M-326.6M-343.7M-333.0M-316.0M-208.1M-142.2M-88.8M-93.6M-120.9M
Interest expense60.9M114.6M128.8M63.5M14.8M9.07M5.92M433.0K618.0K66.0K
Income before tax-351.6M-413.6M-583.9M-417.3M-349.8M-226.0M-160.3M-96.7M-96.9M-121.4M
Income tax-135.0K0-40.0K34.0K9.00K-1.85M-105.0K-503.0K-493.0K-572.0K
Net income-351.4M-413.6M-583.2M-416.6M-346.8M-221.9M-157.8M-96.2M-96.4M-120.8M
Earnings per share, basic-0.38-0.59-1.15-1.04-0.89-0.59-0.43-1.22-1.20-1.47
Earnings per share, diluted-0.38-0.62-1.15-1.04-0.89-0.59-0.43-1.22-1.20-1.47

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents88.3M143.4M265.5M104.6M181.1M34.9M75.8M16.8M23.9M8.08M
Short-term investments154.5M6.38M1.01M2.54M136.0M61.1M36.1M57.3M104.3M190.8M
Receivables42.6M2.36M01.89M1.33M2.00M303.0K12.2M1.26M2.67M
Inventory910.0K8.27M026.4M1
Current assets314.9M184.6M294.1M140.6M334.3M111.7M55.8M88.8M132.5M205.1M
Property, plant and equipment114.3M137.1M146.1M143.7M82.9M72.5M60.5M76.9M76.7M18.9M
Goodwill910.0K910.0K
Total assets501.9M382.9M504.5M362.4M468.9M221.4M143.1M181.9M250.4M317.5M
Accounts payable6.98M6.72M9.20M21.0M11.4M11.5M1.75M2.79M5.87M4.04M
Current liabilities61.8M54.9M58.3M500.9M369.0M68.1M11.6M27.3M20.9M12.6M
Long-term debt477.1M461.9M681.5M241.3M306.3M254.4M
Total debt878.1M504.2M726.7M723.8M645.7M275.5M14.8M6.91M7.27M8.21M
Total liabilities1.00B871.1M1.09B812.2M712.8M339.9M22.4M35.9M31.6M24.1M
Shareholders' equity-500.5M-489.1M-587.0M-447.3M-242.2M-119.8M120.7M146.0M218.8M293.4M
Shares outstanding1.01B852.9M670.9M421.6M397.8M382.2M98.5M79.1M79.0M82.0M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-304.9M-391.2M-366.8M-337.5M-274.4M-171.7M-152.1M-63.4M-48.8M-38.6M
Capital spending-3.85M-6.89M-30.6M-78.2M-33.6M-1.67M-4.29M-13.1M-34.8M-6.56M
Free cash flow-308.8M-398.1M-397.3M-415.7M-308.0M-173.4M-156.4M-76.5M-83.6M-45.2M
Cash from investing-149.8M-12.2M-30.5M27.3M-84.9M-19.8M18.6M57.1M99.6M-113.7M
Cash from financing400.2M281.6M558.3M233.6M505.4M150.7M114.3M-771.0K-35.0M-15.6M
Dividends paid-616.0K-334.4M-4.44M-2.28M
Share buybacks-3.44M-616.0K00-2.50M-228.0K-15.2M-15.8M
Change in cash-54.5M-121.9M160.8M-76.3M146.2M-40.9M-19.3M-7.05M15.8M-167.8M

Open Financials

Filings

FilingDateTypeFiled with
10-Q · Quarterly reportNov 9, 2026Quarterly reportSEC
8-K · Current reportNov 9, 2026ResultsSEC
8-K · Current reportNov 9, 2026Current reportSEC
8-K · Current reportOct 14, 2026Current reportSEC
4 · Change in ownershipOct 6, 2026Insider tradeSEC
4 · Change in ownershipOct 6, 2026Insider tradeSEC
144 · Notice of proposed saleOct 5, 2026Other filingsSEC
144 · Notice of proposed saleOct 2, 2026Other filingsSEC
SCHEDULE 13D/A · Big-stake notice, amendedAug 6, 2026Big-stake noticeSEC
10-Q · Quarterly reportAug 4, 2026Quarterly reportSEC
Show 200 filings
FilingDateTypeFiled with
8-K · Current reportAug 4, 2026ResultsSEC
8-K · Current reportJul 30, 2026Current reportSEC
4 · Change in ownershipJul 6, 2026Insider tradeSEC
4 · Change in ownershipJul 6, 2026Insider tradeSEC
144 · Notice of proposed saleJul 2, 2026Other filingsSEC
4 · Change in ownershipJul 1, 2026Insider tradeSEC
144 · Notice of proposed saleJul 1, 2026Other filingsSEC
144 · Notice of proposed saleJun 30, 2026Other filingsSEC
144 · Notice of proposed saleJun 29, 2026Other filingsSEC
4 · Change in ownershipJun 26, 2026Insider tradeSEC
4 · Change in ownershipJun 10, 2026Insider tradeSEC
4 · Change in ownershipJun 10, 2026Insider tradeSEC
4 · Change in ownershipJun 10, 2026Insider tradeSEC
4 · Change in ownershipJun 10, 2026Insider tradeSEC
4 · Change in ownershipJun 10, 2026Insider tradeSEC
4 · Change in ownershipJun 10, 2026Insider tradeSEC
8-K · Current reportJun 10, 2026Meeting outcomeSEC
4 · Change in ownershipJun 5, 2026Insider tradeSEC
144 · Notice of proposed saleJun 4, 2026Other filingsSEC
8-K · Current reportMay 18, 2026Material contractSEC
10-Q · Quarterly reportMay 7, 2026Quarterly reportSEC
8-K · Current reportMay 7, 2026ResultsSEC
DEFA14A · Additional proxy materialApr 29, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 29, 2026Meeting noticeSEC
ARS · Annual report to shareholdersApr 29, 2026Annual reportSEC
8-K · Current reportApr 9, 2026ResultsSEC
8-K · Current reportApr 6, 2026Current reportSEC
4 · Change in ownershipApr 2, 2026Insider tradeSEC
8-K · Current reportMar 31, 2026Material contractSEC
4 · Change in ownershipFeb 26, 2026Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedFeb 25, 2026Big-stake noticeSEC
4 · Change in ownershipFeb 24, 2026Insider tradeSEC
4 · Change in ownershipFeb 24, 2026Insider tradeSEC
4 · Change in ownershipFeb 24, 2026Insider tradeSEC
4 · Change in ownershipFeb 24, 2026Insider tradeSEC
4 · Change in ownershipFeb 24, 2026Insider tradeSEC
4 · Change in ownershipFeb 24, 2026Insider tradeSEC
10-K · Annual reportFeb 23, 2026Annual reportSEC
144 · Notice of proposed saleFeb 23, 2026Other filingsSEC
8-K · Current reportFeb 23, 2026ResultsSEC
8-K · Current reportFeb 18, 2026Current reportSEC
4 · Change in ownershipFeb 12, 2026Insider tradeSEC
4 · Change in ownershipFeb 12, 2026Insider tradeSEC
4 · Change in ownershipFeb 12, 2026Insider tradeSEC
4 · Change in ownershipFeb 12, 2026Insider tradeSEC
8-K · Current reportJan 26, 2026Material contractSEC
4 · Change in ownershipJan 21, 2026Insider tradeSEC
4 · Change in ownershipJan 21, 2026Insider tradeSEC
144 · Notice of proposed saleJan 20, 2026Other filingsSEC
144 · Notice of proposed saleJan 20, 2026Other filingsSEC
144 · Notice of proposed saleJan 16, 2026Other filingsSEC
8-K · Current reportJan 15, 2026ResultsSEC
8-K · Current reportJan 14, 2026Current reportSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
8-K · Current reportDec 23, 2025Material contractSEC
424B5 · ProspectusDec 23, 2025Offer documentSEC
4 · Change in ownershipDec 16, 2025Insider tradeSEC
3 · Initial statement of ownershipDec 16, 2025Insider tradeSEC
8-K · Current reportDec 15, 2025Management or board changeSEC
8-K · Current reportDec 12, 2025Current reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedNov 10, 2025Big-stake noticeSEC
10-Q · Quarterly reportNov 4, 2025Quarterly reportSEC
8-K · Current reportNov 4, 2025ResultsSEC
DEF 14COct 20, 2025Meeting noticeSEC
PRE 14COct 8, 2025Meeting noticeSEC
8-K · Current reportAug 8, 2025Current reportSEC
10-Q · Quarterly reportAug 5, 2025Quarterly reportSEC
8-K · Current reportAug 5, 2025ResultsSEC
424B5 · ProspectusJul 28, 2025Offer documentSEC
8-K · Current reportJul 25, 2025ResultsSEC
S-8 · Registration statement for employee plansJun 23, 2025Offer documentSEC
4 · Change in ownershipJun 20, 2025Insider tradeSEC
4 · Change in ownershipJun 20, 2025Insider tradeSEC
4 · Change in ownershipJun 20, 2025Insider tradeSEC
4 · Change in ownershipJun 20, 2025Insider tradeSEC
4 · Change in ownershipJun 20, 2025Insider tradeSEC
8-K · Current reportJun 20, 2025Management or board changeSEC
10-Q · Quarterly reportMay 12, 2025Quarterly reportSEC
8-K · Current reportMay 12, 2025ResultsSEC
8-K · Current reportMay 5, 2025Current reportSEC
DEFA14A · Additional proxy materialApr 29, 2025Meeting noticeSEC
ARS · Annual report to shareholdersApr 29, 2025Annual reportSEC
DEF 14A · Proxy statementApr 29, 2025Meeting noticeSEC
8-K · Current reportApr 15, 2025ResultsSEC
424B5 · ProspectusApr 8, 2025Offer documentSEC
8-K · Current reportApr 8, 2025Material contractSEC
8-K · Current reportMar 19, 2025Current reportSEC
10-K · Annual reportMar 3, 2025Annual reportSEC
8-K · Current reportMar 3, 2025ResultsSEC
4 · Change in ownershipFeb 25, 2025Insider tradeSEC
4 · Change in ownershipFeb 25, 2025Insider tradeSEC
4 · Change in ownershipFeb 25, 2025Insider tradeSEC
4 · Change in ownershipFeb 25, 2025Insider tradeSEC
4 · Change in ownershipFeb 25, 2025Insider tradeSEC
8-K · Current reportFeb 12, 2025Management or board changeSEC
4 · Change in ownershipFeb 12, 2025Insider tradeSEC
4 · Change in ownershipFeb 12, 2025Insider tradeSEC
4 · Change in ownershipFeb 12, 2025Insider tradeSEC
4 · Change in ownershipFeb 12, 2025Insider tradeSEC
8-K · Current reportFeb 7, 2025Management or board changeSEC
4 · Change in ownershipJan 24, 2025Insider tradeSEC
4 · Change in ownershipJan 3, 2025Insider tradeSEC
4 · Change in ownershipJan 3, 2025Insider tradeSEC
4 · Change in ownershipDec 16, 2024Insider tradeSEC
4 · Change in ownershipDec 12, 2024Insider tradeSEC
424B5 · ProspectusDec 12, 2024Offer documentSEC
8-K · Current reportDec 11, 2024Material contractSEC
8-K · Current reportDec 10, 2024Current reportSEC
424B5 · ProspectusDec 10, 2024Offer documentSEC
8-K · Current reportNov 19, 2024Current reportSEC
10-Q · Quarterly reportNov 12, 2024Quarterly reportSEC
8-K · Current reportNov 12, 2024ResultsSEC
10-Q · Quarterly reportAug 12, 2024Quarterly reportSEC
8-K · Current reportJul 17, 2024Material contractSEC
S-8 · Registration statement for employee plansJun 20, 2024Offer documentSEC
4 · Change in ownershipJun 13, 2024Insider tradeSEC
4 · Change in ownershipJun 13, 2024Insider tradeSEC
4 · Change in ownershipJun 13, 2024Insider tradeSEC
4 · Change in ownershipJun 13, 2024Insider tradeSEC
4 · Change in ownershipJun 13, 2024Insider tradeSEC
4 · Change in ownershipJun 13, 2024Insider tradeSEC
8-K · Current reportJun 12, 2024Meeting outcomeSEC
10-Q · Quarterly reportMay 9, 2024Quarterly reportSEC
EFFECT · Notice that a registration is effectiveMay 3, 2024Other filingsSEC
CORRESP · Letter to the SECApr 30, 2024Other filingsSEC
DEFA14A · Additional proxy materialApr 29, 2024Meeting noticeSEC
DEF 14A · Proxy statementApr 29, 2024Meeting noticeSEC
ARS · Annual report to shareholdersApr 29, 2024Annual reportSEC
8-K · Current reportApr 23, 2024Current reportSEC
S-3ASR · Registration statementApr 17, 2024Offer documentSEC
UPLOAD · Letter from the SECApr 3, 2024Other filingsSEC
CORRESP · Letter to the SECMar 28, 2024Other filingsSEC
S-3 · Registration statementMar 28, 2024Offer documentSEC
10-K · Annual reportMar 19, 2024Annual reportSEC
4 · Change in ownershipFeb 26, 2024Insider tradeSEC
4 · Change in ownershipFeb 26, 2024Insider tradeSEC
4 · Change in ownershipFeb 26, 2024Insider tradeSEC
4 · Change in ownershipFeb 26, 2024Insider tradeSEC
4 · Change in ownershipFeb 26, 2024Insider tradeSEC
8-K · Current reportFeb 23, 2024Management or board changeSEC
4 · Change in ownershipFeb 6, 2024Insider tradeSEC
4 · Change in ownershipFeb 2, 2024Insider tradeSEC
4 · Change in ownershipFeb 2, 2024Insider tradeSEC
4 · Change in ownershipFeb 2, 2024Insider tradeSEC
SC 13D/A · Big-stake notice, amendedJan 3, 2024Big-stake noticeSEC
4 · Change in ownershipJan 3, 2024Insider tradeSEC
4 · Change in ownershipJan 3, 2024Insider tradeSEC
4 · Change in ownershipJan 3, 2024Insider tradeSEC
8-K · Current reportJan 2, 2024Material contractSEC
4 · Change in ownershipDec 19, 2023Insider tradeSEC
10-Q · Quarterly reportNov 8, 2023Quarterly reportSEC
DEF 14CSep 28, 2023Meeting noticeSEC
DSep 22, 2023Other filingsSEC
SC 13D/A · Big-stake notice, amendedSep 21, 2023Big-stake noticeSEC
PRE 14CSep 15, 2023Meeting noticeSEC
4 · Change in ownershipSep 13, 2023Insider tradeSEC
8-K · Current reportSep 11, 2023Material contractSEC
4 · Change in ownershipSep 6, 2023Insider tradeSEC
4 · Change in ownershipSep 6, 2023Insider tradeSEC
4 · Change in ownershipSep 6, 2023Insider tradeSEC
8-K · Current reportSep 1, 2023Current reportSEC
4 · Change in ownershipAug 28, 2023Insider tradeSEC
4 · Change in ownershipAug 28, 2023Insider tradeSEC
4 · Change in ownershipAug 28, 2023Insider tradeSEC
8-K · Current reportAug 15, 2023Current reportSEC
10-Q · Quarterly reportAug 8, 2023Quarterly reportSEC
424B5 · ProspectusJul 25, 2023Offer documentSEC
424B5 · ProspectusJul 24, 2023Offer documentSEC
8-K · Current reportJul 21, 2023Material contractSEC
8-K · Current reportJul 20, 2023Current reportSEC
4 · Change in ownershipJun 16, 2023Insider tradeSEC
4 · Change in ownershipJun 15, 2023Insider tradeSEC
4 · Change in ownershipJun 15, 2023Insider tradeSEC
4 · Change in ownershipJun 15, 2023Insider tradeSEC
4 · Change in ownershipJun 15, 2023Insider tradeSEC
4 · Change in ownershipJun 15, 2023Insider tradeSEC
4 · Change in ownershipJun 15, 2023Insider tradeSEC
8-K · Current reportJun 14, 2023Material contractSEC
4 · Change in ownershipJun 5, 2023Insider tradeSEC
4 · Change in ownershipJun 5, 2023Insider tradeSEC
4 · Change in ownershipJun 5, 2023Insider tradeSEC
SC 13D/A · Big-stake notice, amendedMay 22, 2023Big-stake noticeSEC
4 · Change in ownershipMay 16, 2023Insider tradeSEC
10-Q · Quarterly reportMay 11, 2023Quarterly reportSEC
8-K · Current reportMay 11, 2023Current reportSEC
DEFA14A · Additional proxy materialApr 28, 2023Meeting noticeSEC
DEF 14A · Proxy statementApr 28, 2023Meeting noticeSEC
ARS · Annual report to shareholdersApr 28, 2023Annual reportSEC
8-K · Current reportMar 31, 2023Material contractSEC

This page holds 200 of 557 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from ImmunityBio, Inc.’s releases · as of Nov 3, 2026

Common shares
1,063,826,073
Fully diluted
1,063,826,073

Fully diluted

LineSharesAs of
Common shares1,063,826,073Nov 3, 2026

Share count over time

CountShares
Nov 3, 20261,063,826,073

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Vanguard41.8M3.9%US$394MSep 30, 2026
BlackRock36.1M3.4%US$341MSep 30, 2026
State Street21.1M2.0%US$199MSep 30, 2026
D. E. Shaw & Co., Inc.10.7M1.0%US$101MSep 30, 2026
Geode Capital10.6M1.00%US$100MSep 30, 2026
Two Sigma5.83M0.55%US$55MSep 30, 2026
Schwab4.93M0.46%US$46.6MSep 30, 2026
UBS4.38M0.41%US$41.4MSep 30, 2026
Goldman Sachs4.13M0.39%US$39MSep 30, 2026
Millennium3.82M0.36%US$36MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Northern Trust3.7M0.35%US$34.9MSep 30, 2026
SEB Asset Management AB2.45M0.23%US$23.1MSep 30, 2026
Morgan Stanley2.13M0.20%US$20.1MSep 30, 2026
Federated Hermes, Inc.1.96M0.18%US$18.5MSep 30, 2026
RBC1.95M0.18%US$18.4MSep 30, 2026
Woodline Partners LP1.9M0.18%US$17.9MSep 30, 2026
Principal1.74M0.16%US$16.4MSep 30, 2026
Bank of America1.72M0.16%US$16.3MSep 30, 2026
JPMorgan1.47M0.14%US$13.1MSep 30, 2026
Marshall Wace, LLP1.45M0.14%US$13.7MSep 30, 2026
BNY1.32M0.12%US$12.4MSep 30, 2026
Trexquant Investment LP1.31M0.12%US$12.4MSep 30, 2026
Cetera Investment Advisers1.22M0.11%US$11.5MSep 30, 2026
Affinity Asset Advisors, LLC1.18M0.11%US$11.1MSep 30, 2026
LPL Financial LLC1.18M0.11%US$11.1MSep 30, 2026
First Trust1.17M0.11%US$11.1MSep 30, 2026
Sound Capital Solutions LLC999K0.09%US$9.43MSep 30, 2026
Osaic Holdings, Inc.897K0.08%US$8.44MSep 30, 2026
Private Advisor Group, LLC885K0.08%US$8.35MSep 30, 2026
Nuveen874K0.08%US$8.25MSep 30, 2026
Janus Henderson874K0.08%US$8.25MSep 30, 2026
Pictet Asset Management Holding SA832K0.08%US$7.39MSep 30, 2026
Swiss National Bank741K0.07%US$7MSep 30, 2026
Winning Points Advisors, LLC730K0.07%US$6.91MSep 30, 2026
Citadel718K0.07%US$6.78MSep 30, 2026
Clearwater Capital Advisors, LLC718K0.07%US$6.77MSep 30, 2026
Allen Holding Inc688K0.06%US$6.49MSep 30, 2026
Voloridge Investment Management, LLC614K0.06%US$5.8MSep 30, 2026
Kercheville Advisors, LLC613K0.06%US$5.79MSep 30, 2026
Invesco559K0.05%US$5.27MSep 30, 2026
Quadrature Capital Ltd549K0.05%US$5.18MSep 30, 2026
D.A. Davidson & Co.542K0.05%US$5.12MSep 30, 2026
Sheets Smith Wealth Management513K0.05%US$4.84MSep 30, 2026
Rafferty Asset Management, LLC506K0.05%US$4.78MSep 30, 2026
State Of Michigan Retirement System500K0.05%US$4.72MSep 30, 2026
Jump Financial, LLC485K0.05%US$4.58MSep 30, 2026
AllianceBernstein485K0.05%US$4.58MSep 30, 2026
Rhumbline Advisers483K0.05%US$4.56MSep 30, 2026
Voya Investment Management LLC482K0.05%US$4.55MSep 30, 2026
T. Rowe Price474K0.04%US$4.48MSep 30, 2026

This page holds 50 of 398 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
State Street(R) SPDR(R) S&P(R) Biotech ETF12.5M1.2%US$109MJun 30, 2026
Vanguard Total Stock Market Index Fund11.6M1.1%US$102MJun 30, 2026
iShares Russell 2000 ETF9.92M0.93%US$86.9MJun 30, 2026
Vanguard Small-Cap Index Fund8.4M0.79%US$73.5MJun 30, 2026
Vanguard Small-Cap Growth Index Fund4.85M0.46%US$42.5MJun 30, 2026
Fidelity Small Cap Index Fund4.22M0.40%US$30.3MJul 31, 2026
Vanguard Extended Market Index Fund3.73M0.35%US$32.6MJun 30, 2026
iShares Russell 2000 Growth ETF3.57M0.34%US$31.2MJun 30, 2026
iShares Biotechnology ETF2.67M0.25%US$23.3MJun 30, 2026
Fidelity Extended Market Index Fund1.58M0.15%US$11.9MMay 31, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Vanguard Russell 2000 Index Fund1.52M0.14%US$11.4MMay 31, 2026
Schwab U.S. Small-Cap ETF1.47M0.14%US$11MMay 31, 2026
Trenchless Fund ETF1.12M0.11%US$9.81MJun 30, 2026
Vanguard Health Care Index Fund1.03M0.10%US$7.77MMay 31, 2026
Schwab Small-Cap Index Fund937K0.09%US$6.72MJul 31, 2026
iShares Genomics Immunology and Healthcare ETF817K0.08%US$5.86MJul 31, 2026
Master Small Cap Index Series709K0.07%US$6.21MJun 30, 2026
Fidelity Nasdaq Composite Index Fund624K0.06%US$4.69MMay 31, 2026
Bridge Builder Small/Mid Cap Growth Fund579K0.05%US$5.07MJun 30, 2026
Fidelity Total Market Index Fund574K0.05%US$4.32MMay 31, 2026
Federated Hermes MDT Small Cap Core Fund565K0.05%US$4.05MJul 31, 2026
First Trust Mid Cap Growth AlphaDEX Fund524K0.05%US$3.76MJul 31, 2026
Federated Hermes MDT Small Cap Growth Fund516K0.05%US$3.7MJul 31, 2026
Nuveen Small Cap Blend Index Fund497K0.05%US$3.56MJul 31, 2026
First Trust Mid Cap Core AlphaDEX Fund471K0.04%US$3.37MJul 31, 2026
WP Large Cap Income Plus Fund465K0.04%US$3.5MMay 31, 2026
Fidelity Series Total Market Index Fund464K0.04%US$3.49MMay 31, 2026
VanEck Social Sentiment ETF436K0.04%US$3.82MJun 30, 2026
iShares Core S&P Total U.S. Stock Market ETF434K0.04%US$3.8MJun 30, 2026
Direxion Daily S&P Biotech Bull 3X Shares423K0.04%US$3.04MJul 31, 2026
EQ/2000 Managed Volatility Portfolio420K0.04%US$3.67MJun 30, 2026
Vanguard Explorer Fund370K0.03%US$2.65MJul 31, 2026
Fidelity Small Cap Growth Index Fund362K0.03%US$3.17MJun 30, 2026
Nuveen Equity Index Fund299K0.03%US$2.15MJul 31, 2026
Vanguard U.S. Momentum Factor ETF298K0.03%US$2.24MMay 31, 2026
LVIP State Street Small-Cap Index Fund273K0.03%US$2.39MJun 30, 2026
Fidelity Nasdaq Composite Index ETF243K0.02%US$1.83MMay 31, 2026
EQ/Small Company Index Portfolio229K0.02%US$2.01MJun 30, 2026
Vanguard Russell 2000 Growth Index Fund228K0.02%US$1.72MMay 31, 2026
Schwab Total Stock Market Index Fund217K0.02%US$1.56MJul 31, 2026
Vanguard Balanced Index Fund195K0.02%US$1.71MJun 30, 2026
Small Cap Index Fund195K0.02%US$1.71MJun 30, 2026
Virtus Biotech Etf191K0.02%US$1.37MJul 31, 2026
Golden Eagle Dynamic Hypergrowth ETF189K0.02%US$1.66MJun 30, 2026
Global X Russell 2000 ETF185K0.02%US$1.33MJul 31, 2026
Fidelity ZERO Total Market Index Fund176K0.02%US$1.26MJul 31, 2026
Schwab U.S. Broad Market ETF172K0.02%US$1.29MMay 31, 2026
Vanguard Institutional Total Stock Market Index Fund172K0.02%US$1.5MJun 30, 2026
Fidelity MSCI Health Care Index ETF171K0.02%US$1.23MJul 31, 2026
First Trust Multi Cap Growth AlphaDEX Fund157K0.01%US$1.13MJul 31, 2026

This page holds 50 of 187 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Simon Barry J.
Director
Sale25,000USD 10.75US$269KOct 5, 2026
Cohen Cheryl
Director
Sale81,056USD 10.50US$851KOct 2, 2026
Cohen Cheryl
Director
Sale131,210USD 9.50US$1.25MJul 2, 2026
Selecky Christobel
Director
Sale159,478USD 9.02US$1.44MJul 1, 2026
Selecky Christobel
Director
Sale1,000USD 9.00US$9,000Jun 30, 2026
Selecky Christobel
Director
Sale95,722USD 9.01US$862KJun 29, 2026
Simon Barry J.
Director
Sale25,000USD 7.88US$197KJun 24, 2026
Simon Barry J.
Director
Sale23,033USD 7.18US$165KJun 4, 2026

Big stakes

StakeStakeSharesDateFiling
Patrick Soon-Shiong66.30%746MFeb 23, 2026Schedule 13D
Cambridge Equities, LP24.70%262MJul 31, 2026Schedule 13D

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Bruce Wendel
Other companies: GT Biopharma, Inc. (Director · Nov 11, 2020 – Jan 27, 2023 · Past); Verastem, Inc. (Director · Jun 14, 2016 – Jun 16, 2020 · Past); Abraxis BioScience Inc (Chief Executive Officer, Director · Nov 7, 2007 – Oct 15, 2010 · Past)
Director · Since at least Dec 12, 2025
Barry Simon
Other companies: Viracta Therapeutics Inc (Director · Mar 3, 2021 – Jun 20, 2024 · Past); Cue Biopharma, Inc. (Director · Jan 4, 2021 – Jan 4, 2021 · Past)
Director · Since at least Dec 22, 2020
Robert Rosen
Other companies: La Jolla Pharmaceutical Co (Director · Jul 7, 2014 – Aug 22, 2022 · Past); Heron Therapeutics, Inc. (President, Director · May 1, 2013 – Dec 15, 2018 · Past)
Director · Jul 27, 2015 – Jul 27, 2015 · Past
Sonja Nelson
Other companies: Ambrx Biopharma Inc. (Chief Financial Officer · Jan 1, 2023 – Mar 7, 2024 · Past); Motus GI Holdings, Inc. (Director · Jun 22, 2021 – Mar 5, 2024 · Past)
Chief Financial Officer · Aug 2, 2019 – Jan 12, 2021 · Past
Cheryl L. Cohen
Other companies: Celldex Therapeutics, Inc. (Director · Since at least Jun 13, 2024)
Director · Since at least Jun 11, 2024
Linda Maxwell
Other companies: United Therapeutics Corporation (Director · Since at least Jul 8, 2021)
Director · Since at least Mar 29, 2021
Regan Lauer
Other companies: Banc of California, Inc. (SVP - CONTROLLER · Dec 31, 2008 – Oct 23, 2012 · Past)
Chief Accounting Officer · Since at least Nov 9, 2021
Wesley Clark
Other companies: Blue Acquisition Corp. (Director · Since at least Jun 12, 2025)
Director · Since at least Jun 14, 2022
Bruce BrownSenior Vice President, Medical Affairs · Since at least Apr 21, 2025
Charles G. GarlisiSenior Vice President, Regulatory Affairs · Since at least Nov 5, 2026
All 28 people
PersonSeat
Christobel SeleckyDirector · Since at least Jun 29, 2026
David SachsChief Financial Officer · Since at least Nov 5, 2026
Elizabeth GabitzschSenior Vice President, Product Development & Vaccine Programs · Since at least Nov 5, 2026
Emily ArisonSenior Vice President of Human Resources · Since at least Nov 5, 2026
Enrique DilonéChief Technology Officer · Since at least Nov 5, 2026
Hemanth RamaprakashInvestor Relations · Since at least May 7, 2026
Jim Yong KimVice Chairman · Since at least Aug 10, 2026
John Owen BrennanDirector · Mar 9, 2021 – Jun 11, 2024 · Past
Leonard S. SenderChief Medical Officer, Liquid Tumors & Cell Therapy · Since at least Nov 5, 2026
Manju SaxenaSenior Vice President of Product Development, Cell Therapy Program · Since at least Nov 5, 2026
Matthew HilmanVice President US Commercial – Urologic Oncology · Since at least Nov 5, 2026
Michael BlaszykDirector · Since at least Nov 5, 2026
Patrick Soon-ShiongExecutive Chairman of the Board · Since at least Oct 21, 2026
Rich AdcockPresident & Chief Executive Officer · Since at least Jan 14, 2026
Richard AdcockCEO & President, Director · Since at least Dec 31, 2023
Richard KusserowDirector · Jun 9, 2017 – Jun 9, 2017 · Past
Sandeep Bobby ReddyChief Medical Officer · Since at least Apr 21, 2025
Sarah SingletonChief Communications Officer & Head of Patient Advocacy · Since at least Oct 8, 2026

Open People

Log in to ask 6ix AI your own questions about ImmunityBio, Inc.